Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
loteprednol etabonate ophthalmic gel 0.38%
- Development stage
- Approved
- Lead developer
- Bausch + Lomb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Ophthalmic
01
Overview
LOTEMAX SM is a topical ophthalmic corticosteroid formulation containing loteprednol etabonate at a concentration of 0.38%. It is specifically designed using submicron (SM) technology, which reduces the particle size of the active ingredient to enhance dissolution in tears and improve ocular tissue penetration and bioavailability compared to previous formulations[10][4]. The drug acts by inhibiting the inflammatory response, thereby reducing pain, swelling, and redness following ocular surgery[3][4]. The formulation includes moisturizing agents such as glycerin and propylene glycol for patient comfort and contains a low concentration of preservative (benzalkonium chloride)[10][6]. Its primary indication is for the treatment of post-operative inflammation and pain following ocular surgery[1][2][3].
- Brand names
- LOTEMAX SM
- Other names
- loteprednol etabonate ophthalmic gel 0.38%
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on loteprednol etabonate ophthalmic gel 0.38%.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on loteprednol etabonate ophthalmic gel 0.38%.